List of Excipients in Branded Drug CETRAXAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Wraser Llc	CETRAXAL	ciprofloxacin	66992-450	GLYCERIN
Wraser Llc	CETRAXAL	ciprofloxacin	66992-450	LACTIC ACID
Wraser Llc	CETRAXAL	ciprofloxacin	66992-450	POVIDONE
Wraser Llc	CETRAXAL	ciprofloxacin	66992-450	SODIUM HYDROXIDE
Wraser Llc	CETRAXAL	ciprofloxacin	66992-450	WATER

Last updated: August 3, 2026

Cetraxal is a preservative-free, single-dose ciprofloxacin otic solution whose commercial value depends more on delivery format, manufacturing reliability, and channel execution than on active-ingredient exclusivity. The strongest opportunities are differentiated unit-dose packaging, pediatric adherence, contract manufacturing, regional licensing, and adjacent otic products. Generic pressure is structurally high because ciprofloxacin is an established small molecule and the formulation is a relatively simple aqueous solution.

Cetraxal Excipient Strategy, Patent Position, and Commercial Opportunities

What is Cetraxal and how is it positioned?

Cetraxal is ciprofloxacin otic solution, 0.2%, indicated for acute otitis externa in patients at least 1 year of age. Each milliliter contains 2 mg of ciprofloxacin. The product is supplied in single-use containers and does not contain an antimicrobial preservative.[1]

The product’s commercial positioning rests on four attributes:

Attribute	Cetraxal position
Active ingredient	Ciprofloxacin
Dosage form	Sterile otic solution
Strength	0.2%, or 2 mg/mL
Delivery format	Preservative-free, single-dose container
Primary indication	Acute otitis externa
Prescription status	Prescription drug
Main commercial advantage	Simple dosing and preservative-free packaging

The key strategic point is that Cetraxal is a delivery-system product rather than a molecule-protection product. Ciprofloxacin has extensive prior clinical and manufacturing history. The product’s defensible value is therefore concentrated in formulation execution, sterile manufacturing, packaging, regulatory documentation, and customer access.

What excipients are used in Cetraxal?

Cetraxal contains a short excipient list. The labeled inactive ingredients are glycerin, polysorbate 20, purified water, and pH-adjusting agents, including hydrochloric acid or sodium hydroxide as needed.[1,2]

Excipient or component	Likely formulation function	Commercial relevance
Glycerin	Tonicity adjustment; contributes to solution properties	Supports patient comfort and compatibility with the external auditory canal
Polysorbate 20	Wetting and solubilization aid	Helps maintain uniform ciprofloxacin distribution and physical stability
Purified water	Vehicle	Enables a low-viscosity, easy-to-administer otic solution
Hydrochloric acid or sodium hydroxide	pH adjustment	Controls product pH and supports chemical stability and tolerability
Ciprofloxacin hydrochloride or equivalent active form	Antibacterial active	Treats susceptible bacterial infection

The formulation is commercially efficient because it avoids a complex excipient platform. That reduces sourcing risk, analytical burden, and the number of formulation parameters that a generic competitor must replicate.

What does glycerin contribute to Cetraxal?

Glycerin primarily supports tonicity adjustment and affects the sensory properties of the drops. In otic products, an isotonic or near-isotonic formulation can improve tolerability, although patient comfort also depends on pH, temperature, dosing volume, infection-related inflammation, and the condition of the tympanic membrane.

Glycerin also has a low regulatory barrier. It is a well-established pharmaceutical excipient with broad supplier availability. Its presence is unlikely to create meaningful formulation exclusivity.

Why is polysorbate 20 used?

Polysorbate 20 is a nonionic surfactant used to improve wetting and solubilization. Its role is important because ciprofloxacin formulations require controlled handling of the active ingredient in an aqueous vehicle.

The main development risks are not ingredient availability but oxidation, impurity control, container interaction, and lot-to-lot consistency. A manufacturer changing surfactant grade, supplier, or concentration would need to assess changes in assay, degradation products, preservative-free sterility controls, visible particles, and container closure performance.

Is Cetraxal preservative-free?

Yes. Cetraxal is labeled without an antimicrobial preservative.[1] That attribute is commercially meaningful in an otic product because it reduces exposure to preservatives that can cause irritation or sensitization in some patients.

Preservative-free status creates a tradeoff. It improves product differentiation and may support pediatric and sensitive-patient positioning, but it requires strict aseptic processing and validated single-dose packaging. A multidose preservative-free product would face a more demanding microbiological and in-use stability strategy.

What formulation patents protect Cetraxal?

Cetraxal’s principal commercial protection does not appear to come from a broad, durable patent estate. The active ingredient is ciprofloxacin, an established generic antibiotic, and the formulation uses conventional excipients in a simple aqueous otic solution.

FDA’s Orange Book identifies approved drug products and any listed patents or regulatory exclusivities associated with them.[3] For Cetraxal, the practical market-access analysis is more important than historical patent claims because:

1. Ciprofloxacin is long off-patent.
2. The core excipients are widely used.
3. The dosage form is a conventional sterile otic solution.
4. Single-dose packaging can be designed around by competitors.
5. Generic manufacturers can pursue an abbreviated pathway where the product-specific regulatory requirements are satisfied.

A formulation patent could still create risk if it claims a narrow combination of concentration, pH, surfactant level, tonicity agent, stability profile, or container system. Such claims would need to be assessed against the actual patent family, prosecution history, claim construction, and Orange Book listing status. The commercial barrier would be materially stronger if the claims covered a clinically important stability or tolerability advantage that could not be designed around.

What excipient claims could create meaningful protection?

The most commercially relevant claim concepts would include:

• A defined ciprofloxacin concentration and pH range.
• A specific glycerin-to-ciprofloxacin ratio.
• A polysorbate 20 concentration range tied to stability or solubility.
• A preservative-free formulation with a defined microbial-control process.
• A single-dose container made from a specific polymer with demonstrated low adsorption.
• A formulation that reduces precipitation after exposure to ear-canal conditions.
• A controlled-volume dispenser that improves dose consistency.
• A combination formulation with a corticosteroid or other anti-inflammatory active.

Broad claims covering glycerin, polysorbate 20, water, and ciprofloxacin would face substantial prior-art and obviousness pressure. Narrow performance-linked claims would have a better chance of surviving examination but would also provide narrower commercial coverage.

When does Cetraxal lose exclusivity?

Cetraxal’s key regulatory exclusivity period has expired. The product was approved by FDA in 2006, and any standard new-drug exclusivity associated with the approval would no longer control market entry.[1,4]

Exclusivity category	Cetraxal assessment
New chemical entity exclusivity	Not applicable; ciprofloxacin was previously approved
Standard 3-year clinical-investigation exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current product-blocking period
Patent-based exclusivity	No broadly durable molecule patent remains
Biosimilar exclusivity	Not applicable; Cetraxal is a small-molecule drug
Current protection	Formulation, brand, packaging, manufacturing, and commercial execution

The product is therefore exposed to generic competition. The relevant question is not whether the original exclusivity remains but whether competitors can obtain approval and supply the product reliably at a lower price.

What is the Orange Book status of Cetraxal?

Cetraxal is associated with an FDA-approved new drug application for ciprofloxacin otic solution.[1,3] The Orange Book remains the controlling public source for listed patents, reference-product status, therapeutic equivalence codes, and approved competitors.

The principal Orange Book implications are:

• The reference product can anchor abbreviated applications.
• A generic applicant may use a Paragraph IV certification if it challenges a listed patent.
• If no blocking listed patent remains, the commercial dispute may shift from patent litigation to approval timing, manufacturing capacity, pricing, and contracting.
• Therapeutic-equivalence status must be reviewed for each approved competitor because the existence of a ciprofloxacin otic product does not by itself establish identical substitution treatment across all markets.

Are there Paragraph IV challenges to Cetraxal?

A Paragraph IV challenge is relevant only if an applicant certifies that a listed patent is invalid, unenforceable, or not infringed. For a legacy ciprofloxacin otic product, Paragraph IV risk is likely to be limited unless a later-listed formulation, device, or method-of-use patent remains active.

The most likely generic entry path is an ANDA referencing the approved ciprofloxacin otic solution. Potential litigation issues would include:

• Whether any listed formulation patent covers the generic composition.
• Whether the generic’s single-dose container infringes a packaging claim.
• Whether the proposed label includes a patented method of use.
• Whether a patent is properly listed for the reference product.
• Whether the generic can use the same preservative-free positioning without infringing a narrow claim.

Because Cetraxal is a small-molecule product, biosimilar litigation is not relevant. Generic litigation, if any, would involve the Hatch-Waxman framework rather than the biologics pathway.

What generic entry risks exist for Cetraxal?

Generic entry risk is high on the active ingredient and dosage-form dimensions. It is lower on the operational dimension because sterile otic manufacturing and single-dose filling require specialized controls.

Risk factor	Impact on Cetraxal
Ciprofloxacin availability	High generic exposure
Simple excipient system	Low design complexity for competitors
Preservative-free format	Raises manufacturing requirements
Single-dose packaging	Adds filling and packaging complexity
Pediatric use	Supports demand but does not block substitution
Sterility requirements	Creates a manufacturing barrier
Brand recognition	May support residual premium pricing
Patent estate	Limited apparent blocking value
Hospital and pharmacy contracting	Can accelerate generic share loss

The most credible generic launch scenario is a lower-priced, preservative-free ciprofloxacin otic solution in unit-dose packaging. A second scenario is a multidose product with a different preservative or container configuration, depending on regulatory acceptability and market demand.

What commercial opportunities exist in Cetraxal excipients?

Premium preservative-free positioning

The current excipient system supports a clean-label and preservative-free proposition. A manufacturer could preserve that position while improving:

• Drop-volume consistency.
• Container ergonomics.
• Opening force.
• Pediatric administration.
• Label readability.
• Tamper evidence.
• Packaging sustainability.

The commercial benefit would be greatest in private-pay, pediatric, urgent-care, and specialist channels where product convenience can influence prescribing or dispensing.

Excipient substitution and supply-chain resilience

A dual-source strategy for glycerin and polysorbate 20 can reduce supply interruption risk. The critical qualification work includes:

• Compendial compliance.
• Residual solvent and peroxide control.
• Endotoxin and bioburden controls.
• Particle profile.
• Compatibility with the active ingredient.
• Extractables and leachables from the unit-dose container.
• Stability under accelerated and long-term conditions.

Polysorbate 20 deserves particular attention because surfactant quality and oxidative impurities can affect stability. A supplier change may be operationally significant even when the nominal excipient remains the same.

Improved unit-dose delivery

The strongest product-development opportunity is likely a better container rather than a novel excipient. Potential improvements include a calibrated dispensing tip, easier opening for caregivers, reduced residual volume, and a container that minimizes contamination during administration.

A device patent or design patent could provide narrower but more practical protection than a conventional excipient patent. The commercial case depends on whether the device can command a premium or secure preferred distribution.

Higher-viscosity or bioadhesive formulations

A controlled-viscosity formulation could increase residence time in the external auditory canal and reduce runoff. Candidate excipients might include established polymers or mucoadhesive agents, but the development burden would increase.

Potential issues include:

• Slower dose distribution.
• Altered patient sensation.
• Impact on ciprofloxacin release.
• Cleaning and manufacturing complexity.
• Compatibility with ear-canal tissue.
• Greater risk of visible particulates or viscosity drift.
• More difficult generic equivalence arguments.

This opportunity is more defensible if clinical data show improved dosing retention, reduced dosing frequency, or better adherence. Without a measurable benefit, the added formulation complexity may not justify a premium.

What combination products compete with Cetraxal?

Cetraxal competes with other topical fluoroquinolones and with antibiotic-corticosteroid otic products. Ciprofloxacin/dexamethasone and ciprofloxacin/fluocinolone products can offer an anti-inflammatory component, which may be attractive when edema, inflammation, or pain is prominent.

Product type	Commercial advantage	Limitation
Ciprofloxacin otic solution	Simple, preservative-free antibacterial treatment	No corticosteroid component
Ciprofloxacin plus dexamethasone	Antibacterial and anti-inflammatory action	More complex formulation and higher cost
Ciprofloxacin plus fluocinolone	Combination therapy with steroid activity	Narrower product positioning
Aminoglycoside-containing otic products	Established clinical use	Greater ototoxicity concerns in some settings
Ofloxacin otic products	Generic availability and broad familiarity	Differentiation may be limited

Combination products offer stronger formulation and method-of-use opportunities, but they also face greater clinical, regulatory, and manufacturing complexity.

What licensing and partnership opportunities exist?

Cetraxal-related commercial opportunities are most likely to involve regional commercialization, private-label supply, or manufacturing partnerships rather than molecule licensing.

Potential counterparties include:

• Regional pharmaceutical companies with established ENT sales forces.
• Generic manufacturers seeking a preservative-free otic platform.
• Contract manufacturers with sterile liquid filling capacity.
• Specialty distributors focused on pediatric or urgent-care products.
• Companies developing otic combination products.
• Device companies supplying unit-dose delivery systems.

A licensing transaction would be more attractive if it included a differentiated package: formulation know-how, validated sterile manufacturing, container specifications, regulatory history, and trademark rights. Rights to the brand alone would offer less strategic value in a genericized market.

How strong is the Cetraxal patent estate?

The patent estate appears commercially weak compared with protected branded products based on novel molecules, long-acting delivery systems, or complex combinations.

Patent dimension	Relative strength
Active ingredient	Very low
Conventional excipients	Low
Basic ciprofloxacin otic solution	Low to moderate
Preservative-free unit-dose format	Moderate if narrowly claimed
Container and dispensing device	Moderate
Manufacturing process	Moderate if difficult to replicate
Combination product	Potentially moderate to strong
Method of use	Dependent on claim scope and remaining term
Brand and trade dress	Ongoing trademark value, not patent exclusivity

The most defensible assets are likely know-how and operational capabilities: sterile filling, container closure validation, stability data, supplier qualification, and regulatory execution.

What FDA regulatory issues affect Cetraxal commercialization?

A new Cetraxal-like product must address the requirements applicable to sterile otic solutions, including:

• Active ingredient identity and assay.
• Sterility assurance.
• Bacterial endotoxin control.
• Particulate matter.
• pH and osmolality.
• Stability and degradation products.
• Container closure integrity.
• Extractables and leachables.
• Dose delivery and residual volume.
• Microbiological quality of the finished product.
• Labeling for age, dosing, and administration.

A formulation that changes excipient type or concentration may trigger additional comparative studies. The regulatory burden is lower for a close formulation copy and higher for a modified-viscosity product, new device, combination product, or extended-duration claim.

What is the revenue exposure from generic entry?

Cetraxal revenue is exposed to rapid price erosion if multiple therapeutically equivalent products enter the market. The largest revenue risks are:

1. Pharmacy substitution.
2. Payer preference for lower-cost generics.
3. Loss of formulary positioning.
4. Distributor reduction of branded inventory.
5. Private-label competition.
6. Contracting pressure from large pharmacy networks.

Brand retention is more plausible where the product has a recognized preservative-free profile, reliable availability, favorable packaging, or strong physician familiarity. A premium strategy requires evidence that these attributes change prescribing or adherence behavior.

What is the most attractive commercial strategy for Cetraxal?

The highest-value strategy is a focused lifecycle program rather than an attempt to extend exclusivity through conventional excipient claims.

Priority 1: Protect the delivery system

Develop a differentiated single-dose container with measurable improvements in dose accuracy, opening, handling, and residual volume. Seek device, packaging, and design protection where available.

Priority 2: Build a supply advantage

Qualify multiple suppliers for glycerin and polysorbate 20, maintain validated alternate sources, and use sterile manufacturing capacity as a commercial differentiator.

Priority 3: Expand the otic platform

Use the formulation and manufacturing platform for:

• Ciprofloxacin/steroid combinations.
• Other preservative-free otic antibiotics.
• Pediatric otic products.
• Short-course products with improved adherence.
• Private-label products for regional markets.

Priority 4: Defend the brand through channel specialization

Focus on ENT specialists, pediatricians, urgent-care clinics, and pharmacies where unit-dose convenience and preservative-free labeling can influence product selection.

Key Takeaways

• Cetraxal is a preservative-free 0.2% ciprofloxacin otic solution in single-dose containers.
• Its excipient system is conventional: glycerin, polysorbate 20, water, and pH adjusters.
• The active ingredient and basic dosage form have high generic exposure.
• Standard regulatory exclusivity has expired.
• Biosimilar risk does not apply; generic and Hatch-Waxman risk does.
• The strongest commercial opportunities are unit-dose devices, sterile manufacturing, supply-chain resilience, regional licensing, and combination otic products.
• Conventional excipient patents are unlikely to provide broad protection.
• A differentiated container, validated manufacturing process, or clinically supported formulation change could create more defensible value.
• Generic entry would likely pressure price, formulary access, and pharmacy share.
• The best lifecycle strategy is platform expansion supported by device and formulation differentiation.

FAQs About Cetraxal Excipient and Commercial Strategy

Can Cetraxal be reformulated without polysorbate 20?

Yes, but removing polysorbate 20 would require redevelopment of solubility, uniformity, stability, particle control, and container-compatibility specifications. The change could also alter regulatory comparability requirements.

Does preservative-free Cetraxal have a patent advantage?

Preservative-free status alone is unlikely to create durable exclusivity. Protection would depend on specific patent claims covering the formulation, manufacturing process, container, or clinically demonstrated performance.

Can Cetraxal be converted into a multidose product?

A multidose version would require a new microbiological and packaging strategy. Without a preservative, the product would need robust contamination-control measures and container technology. A preservative-containing version could lose one of Cetraxal’s principal differentiation points.

Is a ciprofloxacin otic solution eligible for an ANDA?

A competing product may use the ANDA pathway if it meets FDA requirements for pharmaceutical equivalence, bioequivalence or applicable comparative evidence, labeling, quality, and manufacturing. The exact pathway depends on the proposed product and FDA’s reference-product requirements.

Would a ciprofloxacin otic product with higher viscosity be commercially superior?

Not automatically. Higher viscosity may improve retention, but it can also affect comfort, distribution, dose delivery, manufacturing, and regulatory comparability. A premium strategy would require evidence of a clinically meaningful benefit.

References

1. U.S. Food and Drug Administration. (2006). Cetraxal (ciprofloxacin otic solution) prescribing information. FDA.
2. National Library of Medicine. (n.d.). Cetraxal- ciprofloxacin hydrochloride solution. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.